Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Journal: Cancer Research

Published: 2020-11-01

DOI: 10.1158/0008-5472.can-20-1634

Affiliations: 4

Authors: 45

Go to article
Institutions Share
The University of Texas MD Anderson Cancer Center, United States of America (USA) 0.98
Navire Pharma, United States of America (USA) 0.02

Return